Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01684722 · ClinicalTrials.gov registry record · NA
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 1,312
- Enrollment target
NCT01684722: Completed NA study, sponsored by University of Washington.
NCT01684722 is a NA study that has completed, run by University of Washington. The registered enrollment target is 1,312 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01684722, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,312 participants
- Enrollment target
Study Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL with a history of diabetes and will examine whether vitamin D or fish oil prevents the development and progression of diabetic kidney disease.
Primary Outcome
GFR estimated from serum creatinine and cystatin C
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DIETARY_SUPPLEMENT Fish oil placebo
- DRUG Omega-3 fatty acids (fish oil)
- DIETARY_SUPPLEMENT Vitamin D placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,312 participants |
| Start Date | 2010-07 |
| Est. Completion | 2019-11-08 |
| Phase | NA |
What the finished NCT01684722 record still lists
NCT01684722 is an interventional study that assigns participants to a tested intervention. Its 1,312 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Vitamin D is the first listed.
NCT01684722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01684722 about?
NCT01684722 is a clinical study titled "Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease". The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and strok...
What is the current status of trial NCT01684722?
This trial is currently completed. It is a NA study. The enrollment target is 1,312 participants. The study started on 2010-07. Estimated completion is 2019-11-08.
What interventions are being tested in trial NCT01684722?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), Fish oil placebo (DIETARY_SUPPLEMENT), Omega-3 fatty acids (fish oil) (DRUG), Vitamin D placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01684722?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01684722's enrollment target sits among peer trials
1,312 76th of 2000 higher than 1,925 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- NCT06136624 · 1,310 participants · Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia